Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cefuroxime
Drug ID BADD_D00407
Description Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.
Indications and Usage For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.
Marketing Status approved
ATC Code J01DC02; S01AA27
DrugBank ID DB01112
KEGG ID D00262
MeSH ID D002444
PubChem ID 41375
TTD Drug ID D0Y2IE
NDC Product Code 0143-9567; 0143-9569; 0143-9976; 0143-9568; 0143-9977; 0143-9979
UNII O1R9FJ93ED
Synonyms Cefuroxime | Cephuroxime | Zinacef | Ketocef
Chemical Information
Molecular Formula C16H16N4O8S
CAS Registry Number 55268-75-2
SMILES CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Liver disorder09.01.08.001--Not Available
Local reaction08.01.03.012--Not Available
Logorrhoea19.19.02.001; 17.02.08.0060.000143%Not Available
Loss of consciousness17.02.04.0040.001431%Not Available
Lymphadenitis01.09.01.0010.000215%Not Available
Lymphadenopathy01.09.01.0020.000143%Not Available
Macular degeneration06.09.03.0010.000215%Not Available
Macular oedema06.04.06.0050.007297%Not Available
Maculopathy06.09.03.0070.001502%Not Available
Melaena07.12.02.004; 24.07.02.0130.000315%Not Available
Monocytosis01.02.01.0040.000143%Not Available
Mouth ulceration07.05.06.004--Not Available
Muscle spasms15.05.03.004--
Musculoskeletal pain15.03.04.0070.000143%
Myocardial ischaemia24.04.04.010; 02.02.02.0080.000358%Not Available
Myoclonus17.02.05.0080.000143%Not Available
Nausea07.01.07.001--
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
Nervousness19.06.02.0030.000315%Not Available
Neutropenia01.02.03.004--Not Available
Neutrophilia01.02.01.0050.000286%Not Available
Night sweats23.02.03.006; 08.01.03.031--Not Available
Obliterative bronchiolitis12.02.09.036; 10.02.01.096; 22.03.01.0120.000215%Not Available
Ocular hypertension06.03.01.0030.000143%Not Available
Oedema08.01.07.006; 14.05.06.0100.000286%Not Available
Oedema peripheral14.05.06.011; 02.05.04.007; 08.01.07.007--
Optic atrophy06.09.02.0010.001288%Not Available
Osteoporosis15.02.03.002; 14.04.04.002--
Pain08.01.08.004--
Pain in jaw15.02.01.003--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene